Last reviewed · How we verify
Human insulin isophane suspension — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Human insulin isophane suspension (Human insulin isophane suspension) — Eli Lilly and Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Human insulin isophane suspension TARGET | Human insulin isophane suspension | Eli Lilly and Company | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Human insulin isophane suspension CI watch — RSS
- Human insulin isophane suspension CI watch — Atom
- Human insulin isophane suspension CI watch — JSON
- Human insulin isophane suspension alone — RSS
Cite this brief
Drug Landscape (2026). Human insulin isophane suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/human-insulin-isophane-suspension. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab